Means for the suppression of glutamate-induced apoptosis and the inhibition of NMDA receptors with immunomodulatory effects, for the treatment of disorders of the nervous system, resulting in
Хорошилова Галина Владимировна (RU),Коверда Михаил Николаевич (RU),Землянухина Екатерина Сергеевна (RU)
申请号：
RU2013134411/15
公开号：
RU2013134411A
申请日:
2013.07.23
申请国别(地区):
RU
年份:
2015
代理人:
摘要：
1. A drug based on adamantanes or their pharmaceutically acceptable salts for the relief of glutamate-induced apoptosis and inhibition of NMDA receptors for the treatment of disorders of the nervous system, the effects of traumatic brain injury and ischemic and hemorrhagic stroke, characterized in that it contains therapeutically active substance an effective amount of adamantanes or their pharmaceutically acceptable salts and cytidine 5'-diphosphocholine, as well as, optionally, at least one auxiliary a substance selected from the group including stabilizers, prolongators, buffering additives, solvents, fillers, preservatives and other auxiliary substances approved for medical use, in the following ratio, wt.%: 2. The medicine according to claim 1, characterized in that it contains at least one substance selected from the group consisting of Trilon B, sodium metabisulfite, sodium thiosulfate, glycine, arginine, histidine, lysine or their physiologically acceptable salts, for example, as a stabilizer hydrochloride, sulfate, acetate, glutamate, aspartate and maleate, as a prolongator, at least one substance selected from the group consisting of polyvinylpyrrolidone with a molecular weight of 10-60 kDa, dextran with a molecular weight of 10-100 Yes, for example, polyglucin or re opolyglukin, polyvinyl alcohol, sodium carboxymethyl cellulose, as a buffering additive - at least one substance selected from the group consisting of sodium chloride, sodium / potassium hydro- and / or dihydrogen phosphate, sodium or ammonium acetate, as a solvent - at least one �1. Лекарственное средство на основе адамантанов или их фармацевтически приемлемых солей для купирования глутамат-индуцированного апоптоза и ингибирования NMDA-рецепторов для лечения расстройств нервной системы, последствий черепно-мозговой травмы и ишемического и геморрагического инсульта, характеризующаяся тем, что содержит в качестве действующего вещества терапевтически эффективное количество адамантанов или их фар
